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Although many treatment options have been developed to treat Major Depressive 
Disorder, the efficacy of these treatment options remain limited. Past studies on antidepressant 
efficacy have identified a range of cognitive improvements associated with treatments, yet the 
complexity of these studies and the lack of inconsistency across paradigms in existing literature 
hinders the understanding of antidepressant efficacy and highlights the importance of further 
investigation (Atique- Ur-Rehman & Neill, 2019). Additionally, research has indicated 
significant trends in anatomical regions and brain networks, but no single biomarker may exist 
that can be translated across every antidepressant or patient sub-population (Dunlop et al., 2019). 
Despite the inconsistencies in past results, it is clear that abnormalities in cognition and 
functional connectivity are important components of the manifestation of depression and further 
research is necessary to fully understand the mechanisms behind how antidepressants ameliorate 
these symptoms. The overarching purpose of this research is to investigate a more specific niche 
of antidepressant research by analyzing cognitive outcomes, specific to working memory and 
attentional control, and the Citalopram-specific connectivity biomarkers associated with 
treatment in patients. However, this thesis represents the initial steps of this project by assessing 
the validity of specific cognitive tasks, known as Antisaccade, Flanker DL, Operation Span, and 
Symmetry Span, that will be used as the primary behavioral measures of working memory and 
attention in the depressed subjects. Results demonstrate a consistent relationship across task 
performance in subjects and reveal multiple statistically significant correlations between average 
primary measures of the different tasks. This successful validation of these four tasks as 
appropriate measures of attentional control and working memory is crucial before these tasks can 
be applied in the future as primary measures of change in cognition in response to the 




Major Depressive Disorder (MDD) is an incredibly prevalent disease that remains largely 
unsuccessfully treated and understood. Although an abundance of treatment options have been 
developed, the efficacy (ability to alleviate depressive symptoms) and impact of these treatment 
options, such as antidepressant medications and psychotherapy, remain limited. Although the 
anatomical and functional impacts associated with MDD have been investigated, the 
symptomatic expressions and effects of the disease are incredibly individual-dependent and lack 
homogeneity, therefore restricting significant development of treatment efficacy (Arnone, 2019). 
Clinical treatment of MDD often consists of a “trial and error” approach, where patients must 
attempt various antidepressants until finding an option that allows for the most significant 
symptomatic improvement (Dichter et al, 2015). 
In addition to significant changes in mood, past research has established an associated 
decline in various cognitive functions associated with MDD such as executive function, memory, 
attention and processing ability, but this degeneration and the associated mechanism(s) of action 
remains largely misunderstood (Atique-Ur-Rehman & Neill, 2019). In addition to these cognitive 
deficits associated with MDD, research has identified a variety of intrinsic brain networks and 
neurological pathways that demonstrate impairment or altered activity in depressed patients 
compared to controls. Yet, no specific concrete pattern has been identified in these impairments 
of cognitive abilities or changes in functional brain connectivity associated with depression, and 
therefore, the complexity of the neurological mechanisms behind MDD limits advancement and 
understanding of the treatment of the disease. 
Because of the variability in treatment response in patients, it has proven valuable to 
investigate potential biomarkers of antidepressant efficacy via various cognitive function 
assessments and functional Magnetic Resonance Imaging (fMRI). Past studies on antidepressant 
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efficacy have identified a range of cognitive improvements associated with treatments. (Atique- 
Ur-Rehman & Neill, 2019). This is primarily a result of the various types of antidepressants that 
have been investigated, but also a result of the various factors playing a role in the 
aforementioned studies, such as different cognitive assessments used, varied population 
demographics, the severity of MDD, length of study, types of control, etc. The complexity of 
these studies and the lack of inconsistency across current experimental paradigms further hinders 
progress towards understanding antidepressant efficacy and highlights the importance of further 
investigation into these biomarkers. 
Furthermore, a wide range of brain regions have shown significant fluctuations in activity 
and connectivity associated with antidepressant efficacy, but these results aren’t consistent across 
all forms of assessment or even across studies that use similar paradigms (Arnone et al., 2018). 
Research has indicated significant trends in anatomical regions and networks, but there may be 
no single biomarker may exist that can be translated across every antidepressant or patient 
population (Dunlop et al., 2019). Despite this inconsistency, it is clear that abnormalities in 
neurological functional connectivity is an important component of the manifestation of 
depression and further research is necessary to fully understand the mechanisms behind how 
antidepressants impact this network connectivity. 
This study aims to better understand the complex mechanisms behind Major Depressive 
Disorder and mitigate the inconsistency in both past paradigms and results of studies by 
exploring antidepressant efficacy through cognitive-behavioral assessment and simultaneous 
functional Magnetic Resonance Imaging. Over an 8-week period of administration of one of 
the most commonly prescribed and accessible SSRI, known as Citalopram (Celexa), 
researchers hope to further isolate potential biomarkers associated with treatment efficacy by 
analyzing the changes from baseline in cognitive-behavioral tasks, specifically in working 
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memory and attention, and identifying correlations between this change and changes in 
intrinsic functional connectivity. This work will address the need for further investigation of 
the wide variety of brain regions across studies implicated as biomarkers for clinical treatment 































The lack of understanding of the pathophysiology of depression itself has diminished the 
ability to also better understand the clinical efficacy of current anti-depressant therapies. Past 
research into the therapeutic efficacy of anti-depressants in patients with MDD has identified a 
variety of potential cognitive-behavioral and functional connectivity improvements associated 
with treatment administration and decreased depressive symptoms (Arnone, 2019; Atique-Ur-
Rehman & Neill, 2019). However, this wide range of improvements across studies recognized as 
either symptomatic changes resulting from depression or as potential biomarkers for clinical 
treatment efficacy further highlight the demand for further investigation. Inconsistencies in 
experimental procedures and the complexity of the neurological mechanisms behind depression 
establish a need for more exploration of the treatment efficacy, specifically with a more refined 
experimental direction examining recent implications using previously established 
methodologies. 
 
Variation in Outcomes Across Therapies 
Although providing valuable and comprehensive insight into the complexity of 
depression, the lack of homogeneity across experimental procedures and methodologies used in 
current studies investigating anti-depressant efficacy has partially complicated the focus and 
direction of the research. One key inconsistency across studies is the specific antidepressant type 
or brand investigated in the research, as there is a wide variety of specific antidepressants that 
can be prescribed. Recent research indicates that specific classes of antidepressants improve 
different aspects of cognitive function and this has further complicated the understanding of the 
interaction between the antidepressant mechanism of action and cognitive outcomes. One of the 
most commonly prescribed class of antidepressants, Selective Serotonin Reuptake Inhibitors. 
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(SSRIs), such as Vortioxetine and Citalopram, have been shown to improve processing speed, 
executive functioning, working memory, and verbal learning in patients with MDD (Mcintyre 
al., 2018; Zuckerman et al., 2018; Emsley et al., 2018; Lavretsky et al., 2015). Other 
antidepressant types, such as Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and non- 
traditional therapeutic techniques have also shown potential facilitation of cognitive outcomes 
associated with treatment efficacy (Raskin, 2007; Emsley et al., 2018; Lavretsky et al., 2015). 
The variability in cognitive improvement across types of therapies implies that specific 
antidepressants are potentially more effective in improving cognitive impairments in MDD 
patients, but also that each antidepressant therapy may be limited to improvements in only 
specific aspects of cognitive function. In combination with the variability in the disease 
morphology and cognitive symptomatic expression in patients, the inconsistency in therapeutic 
outcomes exacerbates the need for further investigation of the clinical efficacy of antidepressant 
therapies. 
 
Variation in Cognitive-Behavioral Tasks Used 
Another major discrepancy across studies is the variety of cognitive-behavioral 
assessments and tasks that have been used, all of which investigate different cognitive 
mechanisms and therefore indicate different improvements in cognition associated with anti- 
depressant therapies. One of the more common and earlier cognitive behavioral tasks utilized is 
the Digit-Symbol Substitution Test (DSST) that explores a range of cognitive functions, such as 
motor speed, executive function, attention, and others, but more importantly has long served as a 
valid measure of cognitive dysfunction in patients with various psychiatric disorders (Jaeger, 
2018). McIntyre and colleague’s meta-analysis of 3 independent studies that used this DSST as a 
primary measure of cognitive function to investigate potential efficacies of the SSRI vortioxetine  
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indicated significant improvement in cognition (specific to the aforementioned aspects above) 
independent of change in depressive symptoms across all studies (McIntyre et al., 2016).  
Despite this consistency in findings regarding this single type of measure, other studies 
point to other assessments that could serve as therapeutic efficacy measures as well as different 
results regarding the DSST. One study that investigated the efficacy measures of Citalopram 
over an 8-week period by developing a compositive cognitive score from multiple tasks (DSST, 
Stroop, Mini-Mental State Examination (MMSE), Cognition Reflection Test (CRT), Judgement 
of Line Orientation (JOLO), and Serial Reaction Time Task (SRT)) found only significant 
improvement in visuospatial functioning and psychomotor speed. However, this increased 
cognition wasn’t significant compared to the placebo group (Culang et al, 2009). Another study 
later was done by Culang-Reinlieb and colleagues that used another cognitive score composed 
of a different combination of assessments, but also included SRT, MMSE, and Stroop tasks, 
primarily found a significant increase in verbal learning from a baseline instead (Culang-
Reinlieb et al., 2012). 
Investigation using these types of cognitive tasks have been further corroborated by 
Soczynska’s work where treatment using escitalopram was shown to significantly improve 
verbal learning, nonverbal learning, memory, and global function; however, this was discovered 
through a different combination of cognitive assessments, such as California Verbal Learning 
Test (CVLT-II) and Wechsler Memory Scale (Soczynska et al., 2014). The discrepancies across 
cognitive tasks used and the resulting aspects of cognition implicated in treatment efficacy are 
further complicated by the results of Shilyansky’s research, where the IntegNeuro test battery 
(consisting of 9 tasks assessing various domains of cognition) was used as the cognitive outcome 
measure for patients being treated with escitalopram, sertraline or venlafaxine. Yet, despite the 
very comprehensive approach to measuring cognition, the study reported no significant 
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improvements in attention, verbal memory, decision speed, working memory, information 
processing, and motor coordination, while only highlighting some notable improvement in 
executive function and cognitive flexibility (Shilyansky et al., 2016). 
 
Other Inconsistencies Across Study Paradigms 
As seen, this partial insight into the existing research on cognitive biomarkers of 
antidepressant efficacy displays just the surface of the discrepancies in the cognitive measures 
used and the results demonstrated by them. However, the inconsistencies across current studies 
extend beyond just tasks used as primary measures of cognition, as the screening processes, 
various measures of control and other aspects of experimental design fluctuate greatly from one 
study to the next. The aforementioned studies, in combination with others, not only vary in the 
specific antidepressant investigated but also vary in the specific dosage and length of drug 
administration. While these studies all administered SSRIs and possess the same primary 
mechanism of action, these antidepressants have been implicated to have different abilities in 
treating depression and therefore likely exhibit different measurable clinical efficacies across 
these studies (Marken et al., 2000). Additionally, the complexity of the depressive patient 
population itself further complicates the consistency across studies and the ability to control for 
individual differences. Not only does the variation in sample size in investigations have 
important implications, but specifically inconsistencies in the baseline cognition, age range, 
mean age, and gender distribution of the studies’ samples, as the intersectionality of age, 
intelligence or gender differences in depression is not fully understood (Arnone, 2019; Atique-
Ur-Rehman & Neill, 2019; Salk et al., 2017). Moreover, the disparities in symptomatic 
manifestation and severity of MDD in the patient population also introduces new confounds into 
the understanding of treatment efficacy. 
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The current research demonstrates significant efforts to control for these population 
demographics; however, the inconsistency of the methodology across studies for 
approaching the complex population may be further complicating the understanding of anti- 
depressants. More specifically, studies are seen to employ different screening processes and 
associated required depressive criteria for sampled subjects. The majority of studies require 
diagnosis of MDD via the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
criteria and utilize the Montgomery-Åsberg Depression Rating Scale (MADRS) or Hamilton 
Depression Rating Scale (HDRS) as their primary depressive symptomatic outcome measures 
(Atique-Ur-Rehman & Neill, 2019). Yet, the specific score on these depressive inventories 
required for selected patients varies greatly across the field and the impact this might have on 
the symptomatic improvement and efficacy of anti-depressants in sampled patients is unknown. 
Additionally, the specific DSM-IV criteria for selected subjects vary widely, with some studies 
requiring only initial onset MDD, others requiring recurrent MDD, and some even allowing both. 
Other studies further narrow their pooled population demographics through ways such as 
including required criteria such as prior suicide attempt/ideation, no other comorbidities (or 
requiring specific ones), non-psychotic depression, prior inadequate response to antidepressant 
treatment or combinations of any of these (Atique-Ur-Rehman & Neill, 2019). Furthermore, 
some researchers included even more complex screening processes by using a safety evaluation 
component that involves physical examination requirements, measurement of vital signs, 
evaluation of suicidality using the Columbia Suicide Severity Rating Scale (C-SSRS), and other 
various clinical laboratory tests (Mahableshwarkar et al., 2018). The inconsistency of screening 
and sampling techniques across studies further hinders the development of a clear consensus in 
the current understanding of the implications and efficacy measures of anti-depressants, as the 
validity and reliability differences between these designs and criteria measures are not known. 
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The differences in study methodology limit the comparability between studies and this only 
further demonstrates the growing need for standardization across both the screening and 
assessment techniques to more effectively evaluate drug efficacy (Arnone et al., 2018). 
 
Variation in fMRI Techniques and Identified Biomarkers 
Unfortunately, the complexity of identifying biomarkers of clinical efficacy of 
antidepressants doesn’t end there. An array of functional MRI techniques have been used to 
identify the presence of biomarkers for antidepressant efficacy through the analysis of the 
activity of specific regions during resting-state, emotional processing and cognitive task 
performance (Arnone et al., 2018). Investigations that explored neurological activity during 
cognitive tasks have revealed that prefrontal regions show “hypoactivity in depressed patients at 
baseline, but there is improvement in this activity, specifically in areas of the dorsal medial 
frontal gyrus and the dorsolateral prefrontal cortex,” associated with therapeutic intervention 
(Arnone et al., 2018; Lemogne et al., 2010). However, Gyurak and colleagues found significant 
hypoactivity in the dorsolateral prefrontal cortex after 8 weeks of treatment that extended across 
all 3 randomized groups receiving Escitalopram, Sertraline or Venlafaxine (Gyurak et al., 2016). 
Other studies using cognitive assessment tools identified decreased activity in the amygdala- 
hippocampus complex, ventral striatum, and pregenual anterior cingulate cortex associated with 
treatment intervention and symptomatic improvement in patients (Wagner et al., 2010; López- 
Solà et al., 2010, Stoy et al., 2012). 
However, this wide range of regions displaying significant activity fluctuations identified 
above isn’t consistent when emotional processing tasks or resting states are analyzed instead. 
Resting-state data across studies have inconsistently reported decreased and increased 
connectivity from baseline in an array of networks and pathways as a result of treatment 
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administration, with a trend of decreased activity in functional connectivity following treatment 
between medial prefrontal regions, dorsomedial and dorsolateral cortices that connect to the 
default mode network (Arnone et al., 2018; Fu et al., 2015). Additionally, resting-state data 
across studies has further revealed another noticeable pattern of increased connectivity between 
limbic and frontal regions (Lai and Wu, 2012; Wang et al., 2015). Emotional tasks reveal more 
regions of functional connectivity that indicate improvement/change upon treatment 
administration, such as increased activity (or normalization of activity) in the amygdala, anterior 
cingulate cortex and a number of other cortical areas and decreased activity in ventrolateral and 
dorsolateral cortical areas (Godlewska et al., 2016; Delaveau et al., 2016; Victor et al., 2013; 
Ruhé et al., 2012; Arnone et al., 2012). However, these fluctuations in functional connectivity 
are highly dependent on the emotional task used and the directionality of the emotional stimuli 
(positive vs. negative) (Arnone et al., 2018). This review allows only a glimpse into the 
variability in reported functional connectivity outcomes implicated in the efficacy of SSRI’s. 
The complexity of identifying cognitive outcomes and functional connectivity 
biomarkers for treatment efficacy in patients with MDD has been exacerbated by variations in 
cognitive assessments used, study designs, sample characteristics, and fMRI tasks/methodology 
across the research. And as a result, there has been a wide range of cognitive outcomes and 
functional biomarkers implicated in the efficacy of current SSRI therapies, but comparison 
across these results are strictly limited due to the variations in study paradigms and sample 
parameters. However, the development of these broad results indicates not only the need for 
further investigation into the potential efficacy biomarkers for anti-depressants but also the 
importance of approaching the research with a more refined experimental question beyond just 
the clinical efficacy of anti-depressants. Therefore, we hope to investigate a more distinct niche 
of this research by analyzing cognitive outcomes, specific to working memory and attentional 
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control, and the Citalopram-specific biomarkers associated with treatment in patients with MDD, 
as this has become one of the more commonly prescribed anti-depressants (National Alliance on 
Mental Health [NAMI], 2018). Additionally, by adapting methods and study parameters of past 
studies, this work will ideally produce more generalizable results than research has in the past. 
This will simultaneously add insight into the understanding of the therapeutic efficacy of 


















METHODS AND MATERIALS 
Overview of Project Methodology 
  The overarching goal of this project is to eventually assess the treatment efficacy of 
Citalopram on patients with MDD via cognitive-behavioral testing and fMRI; however, it is 
important that the validity of specific cognitive tasks be investigated in a healthy, control subject 
group before the tasks are applied as a measure of cognition, specifically working memory and 
attention, in depressed patients. Therefore, due to time constraints and unforeseen circumstances in 
project development, the majority of the methodology of this thesis is focused on the assessment of 
the validity of cognitive tasks that will be used later as the primary behavioral measures of working 
memory and attention in the depressed subjects. Additionally, it is equally important that this 
piloted control subject data is used for means of comparison to the behavioral data obtained from 
patients with MDD in the future. Moving forward, these cognitive behavioral tasks will be used in 
combination with a separate array of psychometric fMRI tasks to identify potential biomarkers. 
 The tasks used as the primary behavioral measure of cognition in this study are a 
combination of some renowned and some relatively novel tasks, known as the Flanker Deadline 
(DL), Antisaccade, Operation Span, and Symmetry Span tasks, that were specifically developed by 
Randall Engle and colleagues in the Attention and Working Memory Lab at Georgia Institute of 
Technology. Antisaccade and Flanker DL tasks specifically assess attentional control, while 
Operation and Symmetry Span both assess working memory capacity. These tasks not only provide 
a unique assessment of attention and working memory capacity compared to more commonly used 
tasks in previous aforementioned literature, but these tasks have been indicated to produce more 
reliable and valid results, specifically at the individual differences level (Draheim et al., 2019a; 
Draheim et al., 2019b). Existing and traditional attentional measures, such as the Stroop task, rely 
on the use of difference scores, specifically reaction time, as a primary measure; and consequently, 
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researchers argue that this produces unreliable results for individual differences in attentional tasks 
(Draheim et al., 2019a; Draheim et al., 2019b). However, these different attentional control 
measures, specifically Antisaccade and Flanker DL, are primarily accuracy-based, rather than 
based on reaction time difference scores, and collectively have shown to be more reliable and 
produce stronger intercorrelations and associations to working memory measures. It was theorized 
that by using these novel tasks that are potentially better equipped to monitor individual differences 
in cognition and fluid intelligence, this investigation will more effectively assess, compared to 
previous studies, change in attention and working memory in patients being treated with 
antidepressants.  
 
Site of Study 
This research was conducted within the Cognitive Neuroscience at Tech Research 
Laboratory at the Center for Advanced Brain Imaging at Georgia Institute of Technology. All 
cognitive-behavioral testing was administered using E-Prime Psychology Software (Version 
3.0.80) via a Lenovo ThinkCentre M93p (Intel® Core i7-4770 Processor) running on Windows 
Version 7 Enterprise. Any functional connectivity images obtained later will use a 3-Tesla Siemens 
Prisma-Fit Magnetic Resonance Imaging system equipped with 32 channel head coils. 
 
Participants 
6 individuals (age range 18-22, 3 males) participated in the experiment as part of this pilot 
group. This study was facilitated in accordance with the regulations of the Institutional Review 
Board at the Georgia Institute of Technology. All participants were voluntary and gave written 
consent. At the time of consent, participants were administered a safety screening and were 
informed of each task’s instructions. The second component of data collection for this project, 
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which has not been completed, aims to collect data on around 10-15 patients, diagnosed with 
MDD. These patients will be prescribed 20 mg of Citalopram daily, over an 8-week period, but 
will otherwise be administered the same cognitive behavioral procedure (in addition to the fMRI 
task component) both at baseline and after the 8-week period of taking the drug.  
 
Cognitive-Behavioral Procedure 
Subjects performed a comprehensive battery of cognitive-behavioral tasks that assessed 
different aspects of working memory and attention control, consisting of the aforementioned 
Antisaccade task, Flicker DL Task, Operation Span task and the Symmetry Span task, in a 
randomized order. The entire cognitive-behavioral task battery took approximately 60 minutes 
based on individual subject speed. 
 
Flanker DL task (Figure 1).  
For this task, subjects were presented with a black target arrow, pointing to the left or right, 
that appeared above a fixation cross in the center of the screen. The target arrow was presented in 
the middle of an array of other arrows flanking to both sides, but subjects were informed to respond 
only to the direction of the middle arrow. The flanking arrows were either pointing towards the 
opposite direction of the central target arrow (incongruent) or the same direction as the central 
arrow target (congruent). Subjects indicated their response to the target arrow by pressing either 
“z” (target arrow is pointing left) or “/” (target arrow is pointing right). Subjects completed 18 
blocks of 18 trials each (a total of 324 trials). Each single block had 6 incongruent trials and 12 
congruent trails that were presented in randomized order with an interstimulus interval randomized 
between 400-700 milliseconds (ms). 
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However, as opposed to a normal Flanker task used in attention control literature, each trial 
had a response “deadline” that controlled for the amount of time a subject had to response to the 
arrow stimulus (Draheim et al., 2019a; Draheim et al., 2019b). The standard initial deadline for the 
first block of trials was 1050 ms, and the response deadline was consistent between the congruent 
and incongruent trials. If the deadline was reached without the subject pressing a response, the 
stimuli was removed from the screen and subjects were marked as inaccurate for that trial.  
Additionally, this response deadline increased or decreased based on the subject’s accuracy. 
If the subject accurately responded to 15 trials or more within a single block, the response deadline 
decreased; however, if the subject failed to respond accurately to at least 15 trials, the response 
deadline was increased. Furthermore, the amount that the response deadline was changed after a 
block varied depending on the specific block. The first six blocks were either decreased by 90 ms 
or increased by 270 ms for the following block, depending on the subject’s accuracy as mentioned 
before. For the last 12 blocks, the response deadlines were either decreased by 30 ms or increased 
by 90 ms. The differences between subject’s calculated response deadline after the final trial block 





Figure 1. Trial Sequence for the Flanker DL Task. This example shows the trial sequence for the 
Flanker task. After being presented with the fixation cross, the array of arrows appears and the 
subject identified the direction of the central target arrow by using the “Z” (left) and “/” (right) 
keys. If the response deadline is reached without indication of an answer, feedback is provided to 
the subject.  
 
Antisaccade task (Figure 2).  
In this task, subjects were first presented with a fixation cross in the center of a grey screen. 
The fixation cross was presented for a randomized period of time, ranging from 2,000 – 3,000 ms, 
and then a white asterisk (*) was presented to either the left or right side of the screen as a cue for 
the target stimulus. Subjects were instructed to quickly look away from the asterisk cue as a black 
target (either the letter O or Q) would then immediately appear on the opposite side from the 
asterisk cue. The target is presented for 100 ms and then masked by the pattern “##”, requiring 
subjects to quickly classify the target and submit a response. The subjects designated their response 
simply by pressing the “Q” or “O” key on the keyboard as indicated by the target. Once the 
subjects responded, they were presented with accuracy feedback that was followed by an inter-
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stimulus interval of 1,000 ms. Each subject completed a total of 72 trials for this task and overall 
accuracy was obtained.  
 
Figure 2. Trial Sequence for the Antisaccade Task. This example demonstrates the presentation of 
the asterisk cue that directed the subject to look at the opposite side of the screen and identify the 
target, “Q” or “O”. The figure displays the target on the left side of the screen for visual purposes, 
but in this scenario, the target would actually appear on the right. The subjects indicated their 
responses via the Q or O keys on a keyboard. 
 
Operation Span task (Figure 3).  
For this task, subjects were asked to memorize a series of letters presented to them in 
between simple math equations that they were required to accurately solve. A simple math 
equation was presented on the screen first, such as “(5 x 2) – 3”, and the subjects indicated that 
they had arrived at an answer. Next, a proposed answer was presented on the screen (e.g., “(5 x 2) 
– 3 = 7” for the previous problem, and the subject indicated whether the answer was correct or not. 
After indication of their response, a single letter is presented for 800 ms. This process repeated 
until a variable set of letters had been presented, in which the recall screen appeared and subjects 
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were required to recall the correct serial order of the presented letters. This was done by selecting 
from a pool of 12 letters organized in a 4x3 matrix. A blank option was available for subjects to 
mark a letter that was not memorized, but still receive credit for the letters that were successfully 
recalled in that particular set. Feedback on accuracy was provided to the subjects for both the math 
problem and letter recall portions at this point for a period of 2,000 ms.  
A total of 14 trials (2 blocks of 7 trials) was completed by each subject, where the set size 
of letters ranged from 3-8 letters. Each set size was presented once in each of the two blocks in a 
randomized order. Additionally, subjects were administered practice trials of both the math and 
letter components of the task independently and then also combined together before real data 
collection occurred. The set size of the 3 practice blocks (letter recall, math problem-solving, and 
combined) was 3 letters for each of the trials. Average computing speed was calculated throughout 
the experiment, and if a subject took a longer time to solve the math problems than their average 
computed speed plus 2.5xSD, the program would move forward and mark the response as 
incorrect. This automated speed time as a maximum limit was based on the procedure established 
by piloting from the Engle Lab at Georgia Tech (Unsworth et al., 2005). Participants were 
encouraged to keep an 85% accuracy rate or above on the math operations throughout the task. 
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Figure 3. Trial Sequence for the Operation Span Task (Lee & Cho, 2019). The figure above 
displays the alternation between the distractor task (math equation) and the target task (letter 
presentation). The subject first solved a math problem and confirmed if the presented answer was 
true or false. After confirming their response, the first “to be memorized” letter was presented for 
800 ms. A new math equation was then displayed, and this alternating pattern continued until a 
variable set of letters were presented. In the figure, 3 letters were presented, and the subject is 
asked to recall the correct serial order. Accuracy feedback was then provided on both math 
problems and the letter recall. 
 
Symmetry Span task (Figure 4).  
The Symmetry Span task involved a similar paradigm to the aforementioned Operation 
Span, where a distractor task is interspersed between the goal task to assess working memory 
capacity. However, the subject was first presented with a distractor shape within a 16x16 matrix of 
black and white squares, in which they were required to accurately determine if the shape is 
symmetrical along its vertical axis/midline. Therefore, the symmetry portion of this task is self-
paced, similar to the math component portion of Operation Span. After correctly determining the 
shape’s symmetry, a 4x4 grid was presented to the subjects for 800 ms. The subjects were 
instructed to remember the spatial location of a red square within this 4x4 grid. This task 
alternation continued until a randomized number of red square locations had appeared. Upon 
reaching a designated set size of red square locations, the subjects were asked to recall the 
locations of the red squares in the correct serial order.  
There were a total of 12 trials (2 blocks of 6 trials) for subjects to complete. Set sizes of 
squares randomly ranged from 2-7, but each set size was presented once in each of the two blocks. 
Additionally, the practice blocks for this task mirrored the paradigm from the Operation span; 
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therefore, each individual component was practiced until sufficient accuracy (>85%) was reached, 
and then a combined practice block was administered. Practice blocks only involved set sizes of 
red squares ranging from 2-5. Additionally, the average computing speed was also calculated 
throughout this task, and if a subject took a longer time to solve the symmetry problems than their 
average computed speed plus 2.5xSD, the program would move forward and mark the response as 
incorrect. 
 
Figure 4. Difference in Trial Sequence between Operation and Symmetry Span (Foster et al., 
2015). This figures demonstrates the parallels between the Operation and Symmetry Span task 
sequences. For the Symmetry Span task, the distractor task consisted of identifying if a shape was 
symmetrical about a vertical midline, and the target task was to memorize the spatial location of a 
variable set of red squares in the correct serial order. After subject’s were asked to recall the set of 






 For each individual task administered, an .edat3 file was automatically exported upon 
completion of the task by the subject. From here, E-Merge 3.0 was used to merge all subject files 
for each of 4 tasks administered to create 4 merged files, containing all subject data for each 
respective task. These files then were analyzed using E-Data Aid 3.0 to determine the primary 
measures for each subjects’ attempt of the 4 tasks (Final Response DL for Flanker DL, Total 
Accuracy for Antisaccade, and Partial Scan Score for both Operation and Symmetry Span). Any 
necessary secondary measures, specifically reaction time and accuracy for the distractor tasks in 
Operation and Symmetry Span, were also analyzed using E-Data Aid 3.0. The necessary primary 
measure data was imported into Microsoft Excel, which was used to calculate averages and 
standard error across subjects for each task, as described below in further detail. Microsoft Excel 
was also used to generate plots. 
 For Flanker DL, the final response deadline time after the final block for each subject was 
recorded after each attempt at baseline. Then, the average final response deadline and standard 
error were calculated across all subjects. For the Antisaccade task, the total number of correctly 
identified target letters was recorded at the end of all trial blocks. This total number of correct trials 
was divided by the total value of trials (72) to determine the total Antisaccade accuracy for each 
subject (%). The average Antisaccade accuracy and standard error were calculated across all 
subjects. For the Operation and Symmetry Span tasks, the partial span score, which is the total 
number of items (either letters or spatial locations) that were recalled in the correct serial position, 
was obtained at baseline. The average symmetry and operation partial scan scores (and respective 
standard errors) were determined across all subjects as well. Data from subjects who were unable 
to maintain an 85% accuracy rate on the distractor tasks (math equations and symmetry 
components) in both the Operation Span and Symmetry Span were removed from the data set. A 
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Bivariate Pearson Correlation matrix between all 4 tasks’ primary measures was performed using 
the Analyze tool in the IBM SPSS Statistics Data Editor. Pearson correlations calculated were two-
tailed and used alpha values of 0.05 to determine the p-values for each correlation in the matrix and 





















 Each of the 4 tasks contained their own respective primary measures (Final Response 
deadline time for Flanker DL, Total Accuracy Percentage for Antisaccade, and Partial Scan 
Score for both Operation and Symmetry Span). For the Flanker DL task, the average Final 
Flanker Response Deadline time obtained across all subjects was 570.00 ± 67.528 ms. The 
bivariate Pearson Correlation matrix revealed that Flanker DL time was strongly negatively 
correlated with Symmetry Span partial scores, r (4) = -.839, p < 0.05, but only moderately 
negatively correlated with Antisaccade accuracy, r (4) = -.679, p = .138, and Operation Span 
partial scores, r (4) = -.637, p = .174. For the Antisaccade task, the average Total Antisaccade 
Accuracy across all subjects was 78.94 ± 7.327%. Antisaccade accuracy revealed a strong 
positive correlation with both Operation Span partial score, r (4) = .803, p = .055, and with 
Symmetry Span partial score, r (4) = .954, p < .01. For Operation Span, the average Operation 
Span partial score, which represents the total number of correctly recalled letters, across all 
subjects was 67.17 ± 4.324. For the Symmetry Span task, the average Symmetry Span Partial 
Score, which represents the total number of correctly recalled spatial locations, across all 
subjects was 37.67 ± 2.753. The bivariate Pearson correlation matrix revealed a strong positive 
correlation of r (4) = .729, p = .100 between Operation and Symmetry Span partial scores.  
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Figure 1. Final Flanker Response Deadline Time Across Subjects. This figure displays the final 
Flanker Response Deadline Time reached by each subject tested. The final Response Deadline 
Time is the maximum amount of time the subject would be given to respond to the flanker task 
after the final block of trials were completed. The response time was calculated based on the 
accuracy of the subjects’ responses for the current block and would adjust for the next block of 
trials based on this accuracy. If the subject accurately responded to 15 trials or more within a 
single block, the response deadline decreased; however, if the subject failed to respond 
accurately to at least 15 trials, the response deadline was increased. As mentioned before, the 
amount that the response deadline was changed after a block varied depending on the specific 
block. The average Final Response Deadline across all subjects was 570.00 ± 67.528 ms. The 
bivariate Pearson Correlation matrix revealed for Flanker DL a correlation of r (n-2) = -.839, p 
< 0.05 with Symmetry Span, a correlation of r () = -.679, p = .138 with Antisaccade and r () = -


























Figure 2. Total Accuracy for the Antisaccade Task Across Subjects. This figure shows the total 
accuracy across all trials (%) in the Antisaccade task for each subject administered the task. 
There were a total of 72 trials for this task and subjects’ total number of correct responses were 
divided by this total value of trials to determine the total accuracy (%). The average Total 
Antisaccade Accuracy across all subjects was 78.94 ± 7.327%. The bivariate Pearson 
Correlation matrix revealed for Antisaccade a correlation of r (4) = -.803, p = .055 with 
Operation Span, a correlation of r (4) = -.679, p = .138 with Flanker DL and r (4) = .954, p < .01 

































Figure 3. Operation Span Partial Scores Across All Subjects. This figure displays the Operation 
Span partial score for each subject administered the task. The Operation Span partial score is the 
total number of correctly recalled letters across all trials, despite any mistakes in a single trial. In 
comparison, an absolute score (not shown) was also obtained for each subject, which requires a 
stricter criteria by only identifying a response as correct if the entire span of letters in a set were 
correctly recalled. The partial score includes any letter correctly recalled in the total score, 
despite if any other letter in that set was incorrectly recalled. The average Operation Span partial 
score across all subjects was 67.17 ± 4.324. The bivariate Pearson Correlation matrix revealed 
for Operation Span partial scores a correlation of r (4) = -.803, p = .055 with Antisaccade 
accuracy, a correlation of r (4) = -.637, p = .174 with Flanker DL time and r (4) = .729, p = .100 
























Figure 4. Symmetry Span Partial Score Across All Subjects. This figure displays the Symmetry 
Span Partial Score for each subject administered the task. The Symmetry Span Partial Score is 
the total number of correctly recalled red square spatial locations across all trials, despite any 
mistakes in a single trial. In comparison, an absolute score (not shown) was also obtained for 
each subject, which requires a stricter criteria by only identifying a response as correct if the 
entire span of spatial locations in a set were correctly recalled. The partial score counts all 
spatial location correctly recalled towards the total score, despite if any other letter in that set 
was incorrectly recalled. The average Symmetry Span Partial Score across all subjects was 
37.67 ± 2.753. The bivariate Pearson Correlation matrix revealed for Symmetry Span partial 
scores a correlation of r (4) = -.954, p < .01 with Antisaccade accuracy, a correlation of r (4) = -




























 At first glance, the preliminary results from the 4 tasks demonstrate a consistent trend; 
subjects that showed higher performance on the attentional tasks (faster Final Flanker response 
deadline time and higher Antisaccade accuracy) also showed higher performance on the 
working memory tasks (higher partial span score). More specifically, subjects 1 and 2 
consistently showed the lowest performance on all 4 tasks, while subject 4 mostly performed at 
the highest level across tasks. This trend infers some level of validation of these tasks, as those 
subjects’ who demonstrate lower intelligence or cognition level on one task are consistently 
doing so on different types of tasks that assess different aspects of cognition. Furthermore, the 
trend is even consistent across the tasks that test the same cognitive function but vary in 
methodology. For example, subjects who performed less accurately on the Antisaccade task also 
demonstrated a slower final response deadline on the Flanker DL task, which both assessed 
attentional control, but through different paradigms.  
The Antisaccade task is often viewed as a “hallmark” measure of attention control in this 
field, and past research has revealed strong, statistically significant correlations between the 
Antisaccade task and the Flanker DL task (Draheim et al., 2019a). Furthermore, past work has 
shown that Antisaccade and Flanker DL are two of the best indicators of attentional control 
based on reliabilities and intercorrelations and their strong relationship to working memory 
capacity and fluid intelligence. Our work demonstrated a moderately strong negative correlation 
of r = -.679 (p = .138) between the Flanker DL final response deadline (ms) and the Antisaccade 
total accuracy. Therefore, a relationship seems to exist in which subjects who reached a faster 
response deadline time on the Flanker DL task were also scoring more accurately on the 
Antisaccade task. This correlation, although not significant, corresponds to past work and 
partially supports how both tasks assess processing components of attentional control.  
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All correlations established between task results were either moderately strong or strong, 
but the 2 significant correlations found were between Symmetry Span and both Flanker DL (r () 
= -.839, p < .05) and Antisaccade (r (n-2) = .954, p < .01). Flanker DL and Antisaccade have 
been indicated to be more strongly correlated with measures of working memory capacity in 
comparison to other attentional control measures and these significant correlations calculated 
demonstrate that relationship (Draheim et al., 2019a). However, this same strength of replication 
is not reflected with Operation Span, another measure of working memory capacity like 
Symmetry Span. This could suggest that Symmetry and Operation Span measure different 
aspects or mechanisms of working memory processing, and this variation in paradigm between 
the 2 tasks allows Symmetry Span to be more strongly correlated with these measures of 
attentional control.  
 An empirical test and validation assessment has been previously performed by 
researchers (Draheim et al., 2019a) on a variety of measures of attentional processing, including 
the 4 tasks we administered, and comparison of primary measure averages to the values 
determined in this study is important. The average data values obtained from the 4 tasks here 
display both consistency and inconsistency with the average standard values determined in this 
empirical study performed on a sample of 396 subjects. Compared to the average Final Flanker 
Response Deadline of 570.00 ms we obtained here, Draheim and researchers (2019a) 
determined a higher average Final Response Deadline of 674.61 ms across all subjects. The 
average Antisaccade accuracy rate we obtained was 78.84%, and Draheim and researchers 
demonstrated a substantially close average Antisaccade accuracy of 79.00%. Yet, the Operation 
and Symmetry Span partial scores obtained by Draheim et al. (2019a) were not as comparable to 
values found in this work. The Operation Span partial score obtained here was 67.17, while past 
researchers isolated a smaller value of 55.76. Additionally, while the average Symmetry Span 
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partial score obtained here was 37.67, the Symmetry Span partial score indicated in this 
empirical research was also lower, at a value of 27.90 (Draheim et al., 2019a). Although only 
the Total Antisaccade Accuracy was in close proximity to previously established values, the 3 
inconsistent primary measures for the tasks still displayed a consistent trend of higher cognitive 
performance across the board, i.e. lower response deadline, higher operation span and symmetry 
span partial scores, compared to the averages demonstrated by past research.  
The inconsistency shown between previously established average values and the 
obtained results could be a consequence of the small sample size used (n=6) and the sample 
size’s less accurate representation of the general population. The sampling methods used, such 
as only assessing Georgia Tech students as control participants, is likely less representative of 
the average population and could influence the higher (or faster) average values for the Flanker 
DL, Operation Span, and Symmetry Task. Another limitation of this research is that the Flanker 
DL and Antisaccade tasks, although reliable, may be demonstrating only task-specific 
processing within attentional control and could be an incomplete representation of attention. 
More specifically, although these 2 tasks measure important attention-related processing, these 
tasks could to some extent measure only specific mechanisms of attention and this could limit 
the scope of their use as measure of change in cognition in patients with MDD. This also goes 
for the Operation Span and Symmetry Span tasks, as both could be assessing only a component 
of working memory processing as limited by their methodological design.  Furthermore, 
uncontrolled extraneous variables, such as task administration fluidity and subject motivation, 





 The validation of these 4 tasks as appropriate measures of attentional control and 
working memory is crucial before these tasks can be applied as primary measures of change in 
cognition in response to the administration of an anti-depressant. Although the validation and 
proper testing of these tasks in a healthy, control population is an important step, the overall end 
goal of this project remains to identify biomarkers for Citalopram efficacy using a combination 
of cognitive-behavioral assessment and functional Magnetic Resonance Imaging. Additionally, 
it is equally important that this piloted control subject data is used for means of comparison to 
the behavioral data obtained from patients with MDD in the future. Because some significantly, 
strong correlations between the 4 tasks were obtained, researchers will continue to assess the 
validity of these tasks and hope to administer them in patients with MDD over an 8-week period 
to assess change in attentional control and working memory from baseline. Moving forward, 
these cognitive behavioral tasks will be used in combination with a separate array of 
psychometric fMRI tasks that have already previously been validated to potentially isolate 
correlations between changes in cognitive performance and in functional connectivity as a result 
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